NCT02800642 - Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

June 10, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

Central Retinal Vein Occlusion

Interventions

DRUG

Aflibercept (Eylea, BAY86-5321)

The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.

Trial Locations (42)

2000

Sydney

2150

Parramatta

2600

Glostrup Municipality

2640

Albury

9100

Aalborg

20132

Milan

20157

Milan

30625

Hannover

33012

Oviedo

33076

Bordeaux

35128

Padua

37075

Göttingen

40225

Düsseldorf

48149

Münster

50935

Cologne

56124

Pisa

60126

Ancona

69004

Lyon

69120

Heidelberg

76133

Karlsruhe

79106

Freiburg im Breisgau

86156

Augsburg

T2H 0C8

Calgary

L8G 5E4

Hamilton

N6A 4V2

London

J7H 1S6

Boisbriand

J1G 2V4

Sherbrooke

G1V 1T6

Québec

BP 1542-21

Dijon

04103

Leipzig

00133

Rome

00198

Rome

08195

Sant Cugat Del Vallés

08840

Viladecans

08024

Barcelona

08025

Barcelona

SR2 9HP

Sunderland

BD9 6RJ

Bradford

BS1 2LX

Bristol

CO3 3NB

Colchester

L9 7AL

Liverpool

OX3 9DU

Oxford